Rating Change
Canaccord Genuity reiterated its Buy rating on Niagen Bioscience Inc (NASDAQ:NAGE) on November 06, 2026.
Canaccord Genuity reiterated its Buy rating on Niagen Bioscience Inc (NASDAQ:NAGE) on November 06, 2026.

At publication ·
Niagen Bioscience Inc (NASDAQ:NAGE) · reiterate
At a glance
Canaccord Genuity reiterated its Buy rating on Niagen Bioscience Inc (NASDAQ:NAGE) on November 06, 2026.
Niagen Bioscience Inc operates in the Healthcare sector. The stock currently trades at $2.07 with a market capitalization of $529.9M.
Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Niagen Bioscience Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 06, 2026 | Canaccord Genuity | Buy | N/A |
| Nov 06, 2026 | Freedom Broker | Buy | N/A |
| Oct 30, 2026 | Canaccord Genuity | Buy | N/A |
| May 11, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 05, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View NAGE Stock Page
A rating of Buy from Canaccord Genuity reflects the analyst's outlook on Niagen Bioscience Inc (NASDAQ:NAGE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NAGE forecast page.
Current market data
NASDAQ · NAGE
Keep reading